Iftequar Siddiqui, MD
Interventional Pain Medicine · Tucson, AZNPI 1548536469
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Medtronic at 25.8% of the total. Reporting peaked in 2023 at $793 and has fallen 71.5% since, to $226 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in AZ, where the typical reported total is $8,993.
Across 59 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$453
- Collegium Pharmaceutical, Inc.$387
- AbbVie$152
- Averitas Pharma Inc.$145
- GSK$125
- SPR Therapeutics, Inc$101
- plus $395 from 14 others
What the payments were for
- Food & beverage$1,758100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 8 | $453 |
| Collegium Pharmaceutical, Inc. | 19 | $387 |
| AbbVie | 8 | $152 |
| Averitas Pharma Inc. | 2 | $145 |
| GSK | 1 | $125 |
| SPR Therapeutics, Inc | 2 | $101 |
| Nalu Medical, Inc. | 1 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Vertos Medical, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Tonix Medicines, Inc. | 2 | $31 |
| Relievant Medsystems, Inc. | 1 | $25 |
| Pfizer | 1 | $24 |
| Pacira Therapeutics, Inc. | 1 | $21 |
| GRT US Holding, Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| Avanos Medical | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$178
- Qutenza$129
- TRELEGY ELLIPTA$125
How this compares
$1,758 in reported general payments places this provider in the 20th percentile of 64 interventional pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 67 | $28,589 |
| NucyntaTapentadol Hcl | 20 | $23,138 |
| BelbucaBuprenorphine Hcl | 44 | $20,502 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 526 | $14,727 |
| Pregabalin | 656 | $14,259 |
| Buprenorphine | 42 | $8,323 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 255 | $7,394 |
| Gabapentin | 302 | $4,546 |
| Tramadol Hcl | 552 | $4,419 |
| Morphine Sulfate | 143 | $3,329 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 104 | $3,008 |
| Tizanidine Hcl | 125 | $2,494 |
| Oxycodone Hcl | 112 | $1,895 |
| Methocarbamol | 73 | $1,530 |
| Naloxone Hcl | 23 | $1,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Belbuca | $387 | $72,229131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 64 interventional pain medicine providers in Arizona.
Other interventional pain medicine in Tucson
- Kyung ChenTucson$16K
- Bradley HoltTucson$15K
- Stephen ShillerTucson$3K
- Paul LynchScottsdale$283K
- Jack DiepLake Havasu City$233K
- Matthew RansonMesa$86K
- Steven SiwekPhoenix$57K
- Ajay YedduGilbert$52K
- Ramoun JonesPhoenix$51K
- Lisa StearnsPhoenix$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.